Related Experiment Video
Updated: Apr 12, 2026
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment
Scott A Tomlins1, John R Day2, Robert J Lonigro3
1Michigan Center for Translational Pathology, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA; Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI, USA.
Urine-based biomarkers TMPRSS2:ERG and PCA3 significantly improve prostate cancer (PCa) detection when combined with PSA levels. The Mi-Prostate Score (MiPS) offers a more accurate prediction of PCa and high-grade PCa on biopsy.
Area of Science:
- Urology
- Biomarker Discovery
- Prostate Cancer Diagnostics
Background:
- TMPRSS2:ERG (T2:ERG) and prostate cancer antigen 3 (PCA3) are advanced urine-based biomarkers for early prostate cancer (PCa) detection.
- Current diagnostic approaches often rely on serum prostate-specific antigen (PSA) or risk calculators, which have limitations in accuracy.
Purpose of the Study:
- To validate logistic regression models, known as Mi-Prostate Score (MiPS), for predicting PCa and high-grade PCa.
- To assess the performance of MiPS models incorporating serum PSA (or PCPTrc) with urine T2:ERG and PCA3 scores.
Main Methods:
- Utilized clinical-grade transcription-mediated amplification assays to generate T2:ERG and PCA3 scores.
- Applied pretrained MiPS models to a validation cohort of 1244 men undergoing biopsy.
- Compared model performance using Area Under the Curve (AUC) and Decision Curve Analysis (DCA).
Main Results:
- Models incorporating T2:ERG demonstrated significantly higher AUC than PSA or PCPTrc alone for predicting PCa and high-grade PCa.
- MiPS models with T2:ERG showed superior AUC compared to models using only PCA3 plus PSA or PCPTrc.
- DCA confirmed the clinical benefit of MiPS models over traditional risk calculators.
Conclusions:
- The integration of urine T2:ERG and PCA3 scores enhances the predictive performance of serum PSA or PCPTrc for PCa detection.
- The validated Mi-Prostate Score (MiPS) provides a clinically available tool for individualized risk assessment of prostate cancer.
